These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 10997946

  • 1. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y.
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [Abstract] [Full Text] [Related]

  • 2. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
    Achira M, Suzuki H, Ito K, Sugiyama Y.
    AAPS PharmSci; 1999 Oct; 1(4):E18. PubMed ID: 11741214
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
    Katoh M, Nakajima M, Yamazaki H, Yokoi T.
    Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223
    [Abstract] [Full Text] [Related]

  • 4. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C, Dalton JT, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, Schuetz EG.
    Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
    Katoh M, Nakajima M, Yamazaki H, Yokoi T.
    Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
    [Abstract] [Full Text] [Related]

  • 7. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.
    Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF.
    J Pharmacol Exp Ther; 2002 Aug; 302(2):645-50. PubMed ID: 12130727
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
    Baron JM, Goh LB, Yao D, Wolf CR, Friedberg T.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):351-8. PubMed ID: 11160617
    [Abstract] [Full Text] [Related]

  • 10. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A, Satoh H, Thomas PE, Bush E, Moore D.
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [Abstract] [Full Text] [Related]

  • 11. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4.
    Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y.
    J Pharmacol Exp Ther; 2000 Apr; 293(1):230-6. PubMed ID: 10734174
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
    Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K.
    Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.
    Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K.
    J Pharm Pharmacol; 2005 Jun; 57(6):759-64. PubMed ID: 15969931
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 19. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
    Iwanaga K, Hayashi M, Hamahata Y, Miyazaki M, Shibano M, Taniguchi M, Baba K, Kakemi M.
    Drug Metab Dispos; 2010 Aug 15; 38(8):1286-94. PubMed ID: 20463004
    [Abstract] [Full Text] [Related]

  • 20. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
    Patel J, Buddha B, Dey S, Pal D, Mitra AK.
    Am J Ther; 2004 Aug 15; 11(4):262-77. PubMed ID: 15266218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.